Tonix Pharmaceuticals HoldinTNXP
13F holders, Q2 2024 (June 30)2holders −38
1new positions
40sold out
$0.70avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Tonix Pharmaceuticals Holdin (TNXP) in their 13F filings, down 38 from Q1 2024. 1 opened new positions and 40 sold out. The largest holders were Rosalind Advisors, Inc. ($20K) and Twin Lakes Capital Management, LLC ($1).
- Company
- Tonix Pharmaceuticals Holdin
- CUSIP
- 890260854
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1 |
| Exits | 40 | $2.1M |
All 13F filers, Q1 2024 → Q2 2024: 1 shares bought and 11,995,603 shares sold, net −11,995,602 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Rosalind Advisors, Inc. | 0.02% | Reduce -96.9% | 28,154 | $20K |
| Twin Lakes Capital Management, LLC | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is TNXP's weight in each manager's 13F, not the share of Tonix Pharmaceuticals Holdin the manager owns.